Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-01

Study Completion Date

2024-09-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project will describe the role of physiological levels of GLP-2 in regulating the blood flow to the intestines and the effect of the antagonist GLP-2(3-33) in blocking these effects of GLP-2.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Role of GIP and GLP-2 in Postprandial Splanchnic Blood Flow Distribution and Metabolism

NCT05391581

Blood Flow

COMPLETED NA

The Effect of GLP-1 on the Inhibition of Glucagon Secretion

NCT01507597

Type 2 Diabetes Type 1 Diabetes

COMPLETED NA

GLP-2 (Glucagonlike Peptide-2) and Blood Flow

NCT00540215

Regional Blood Flow

COMPLETED NA

Investigation of GLP-2 Mechanism of Action (GA-8)

NCT03159741

Healthy

COMPLETED NA

Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?

NCT03954873

Glucose Metabolism Disorders Endocrine or Metabolic Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ten healthy participants will meet fasting and attend four randomized experimental days of MRI-scans of the abdomen. Each day will include subcutaneous injections of GLP-2 or saline and intravenous infusion of either the GLP-2 (3-33) antagonist or saline. The infusion start at timepoint -20, while the subcutaneous injection is given to timepoint 0 and the participant will lay in the scanner in one hour after injection. Eight MR-scans are done repeatedly to measure the blood flow in larger abdominal vessels and four blood samples are taken during the experimental day for analysis of GLP-2(1-33), GLP-2(3-33) and bone markers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomised, placebo-controlled, single-blinded, crossover-study

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Saline injection + Saline infusion (SAL-SAL)

Saline subcutaneous injection, Intravenous saline infusion (NaCl (9 mg/ml))

Group Type PLACEBO_COMPARATOR

Saline infusion

Intervention Type OTHER

Saline/NaCl (9mg/ml) intravenous infusion

Saline injection

Intervention Type OTHER

Saline/NaCl (9mg/ml) subcutaneous injection

GLP-2 agonist injection + Saline infusion (AGO-SAL)

Subcutaneous injection of GLP-2 (1-33) agonist, Intravenous infusion of saline (NaCl (9 mg/ml))

Group Type ACTIVE_COMPARATOR

Saline infusion

Intervention Type OTHER

Saline/NaCl (9mg/ml) intravenous infusion

Agonist injection

Intervention Type OTHER

GLP-2(1-33) subcutaneous injection

GLP-2 agonist injection + GLP-2 1 nmol antagonist infusion (AGO-1ANT)

Subcutaneous Injection of GLP-2 (1-33) agonist, Intravenous infusion of 1 nmol/kg/min GLP-2 (3-33) antagonist

Group Type EXPERIMENTAL

1nmol antagonist infusion

Intervention Type OTHER

GLP-2 (1-33)/GLP-2(3-33) 1 nmol/kg/min

Agonist injection

Intervention Type OTHER

GLP-2(1-33) subcutaneous injection

GLP-2 agonist injection + GLP-2 4 nmol antagonist infusion (AGO-4ANT)

Subcutaneous Injection of GLP-2 (1-33) agonist, Intravenous infusion of 4 nmol/kg/min GLP-2 (3-33) antagonist

Group Type EXPERIMENTAL

4 nmol antagonist infusion

Intervention Type OTHER

GLP-2 (1-33)/GLP-2 (3-33) 4 nmol/kg/min

Agonist injection

Intervention Type OTHER

GLP-2(1-33) subcutaneous injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Saline infusion

Saline/NaCl (9mg/ml) intravenous infusion

Intervention Type OTHER

Saline injection

Saline/NaCl (9mg/ml) subcutaneous injection

Intervention Type OTHER

1nmol antagonist infusion

GLP-2 (1-33)/GLP-2(3-33) 1 nmol/kg/min

Intervention Type OTHER

4 nmol antagonist infusion

GLP-2 (1-33)/GLP-2 (3-33) 4 nmol/kg/min

Intervention Type OTHER

Agonist injection

GLP-2(1-33) subcutaneous injection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-70 years
* BMI 19-28 kg/m2

Exclusion Criteria

* Chronic illness that affects the cardiovascular system or gastrointestinal tract
* Treatment with medicine or supplements that cannot be paused for 12 hours
* Intake of above 14 alcoholic drinks per week or substance abuse
* Liver enzymes (ALAT) above 2 times normal values
* Decreased kidney function (eGFR below 90 or creatinine levels over reference value)
* Low blood percentage (hemoglobin below reference value)
* Any condition or disease that the persons responsible for the study find would interfere with the participation of the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes